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ABSTRACT
Background and the purpose of the study: Studies show that chitosan nanoparticles increase 
mucoadhesivity and penetration of large molecules across mucosal surface. The aim of the present 
study was to investigate the use of thiolated chitosan in the development of polysaccharide-
coated nanoparticles in order to confer specific functionality to the system.
Methods:  Methyl  methacrylate  nanoparticles  were  coated  with  thiolated  chitosan  using  a 
radical polymerization method. Thiolation was carried out using glutathione (GSH) to improve 
mucoadhesivity and permeation enhancing properties of chitosan. Mucoadhesion studies were 
carried out by calculating the amount of mucin adsorbed on nanoparticles in a specific period 
of time. Complement consumption was assessed in human serum (HS) by measurement of the 
hemolytic capacity of the complement system after contact with nanoparticles.
Results:  The  FT-IR  and  1HNMR  spectra  both  confirmed  the  synthesis  and  showed  the 
conjugation of thiolated chitosan to methyl methacrylate (MMA) homopolymer. Nanoparticles 
were spherical having a mean diameter within the range of about 334-650 nm and their positive 
zeta potential values indicated the presence of the cationic polysaccharide at the nanoparticle 
surface. Increasing the amount of thiolated chitosan led to mucoadhesivity and complement 
activation. However there was not dose dependent correlation between these phenomenons and 
the absence of thiolated chitosan led to particles with larger size, and without ability to activate 
complement process.
Major conclusion: It can be concluded that nanoparticles could be used for the mucosal delivery 
of peptides and proteins. Results show that the thiolated chitosan had higher mucoadhesion and 
complement activation than unmodified chitosan.
Keywords: Thiolated chitosan, Complement consumption, Glutathione, Mucosal drug delivery, 
Nanoparticles
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INTRODUCTION
Surface  modified  nanoparticles  of  polymers  have 
received much attention as drug carriers. Such 
nanoparticles  have  been  modified  for  specific 
objectives.  The  shell  characteristics  of  core-shell 
nanoparticles are more important than those of the 
cores, as the shell layer directly contacts body fluids 
and organs. Generally the nanoparticles are coated 
with hydrophilic polymer in order to give long-lasting 
half-lives in circulation, and are usually conjugated 
with functional ligands or proteins for site specific 
delivery (1). In this view, methods for the synthesis of 
nanoparticles composed of a polyalkylcyanoacrylate 
core  coated  with  polysaccharides  are  particularly 
attractive because both the amphiphilic copolymer 
and the nanoparticles can be obtained in a single 
step.  This  can  be  achieved  by  the  formation  of 
a free radical at the end of the polysaccharide 
chain  through  oxidation  of  the  reaction  with 
Cerium (IV) ions in aqueous acidic medium. The 
polymerization  of  alkylcyanoacrylate  (ACA) 
monomers is then initiated by these radicals, 
leading to linear block copolymers that undergo 
spontaneous auto-association to form nanoparticles 
with a hydrophobic core coated by the hydrophilic 
polysaccharide. This radical polymerization method 
has been tested using different polysaccharides 
including dextran, dextran sulfate, chitosan and in 
all cases have provided very suitable suspensions of 
nanoparticles (2, 3). 
It is anticipated that with further characterization and 
adjustments these nanoparticles can deliver drugs to 
their targets. In this article a polymethylmethacrylate 
coated  with  thiolated  chitosan  conjugates  is 
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described.  Thiolated  polymers  (thiomers)  improve 
the uptake of hydrophilic macromolecules from the 
GI tract, and it is hoped that this product to be tested 
for carrying capacity, size, and future utility (3, 4). 
Chitosan, a natural-based polymer obtained by 
alkaline deacetylation of chitin, is nontoxic, 
biocompatible and biodegradable (3, 5-8). Thiolation 
of chitosan has been shown to improve the polymer 
intrinsic mucoadhesivity property due to formation 
of disulphide bonds with cysteine-rich domains of 
mucus glycoproteins (2). Permeation enhancing as 
well as cohesive properties that increase the stability 
of  a  delivery  system  are  also  achieved  (9).  The 
purpose of the present study was to synthesize and 
characterize  poly–methyl-methacrylate  (PMMA) 
nanoparticles  coated  with  Chitosan-glutathione 
(GSH)  conjugate  and  to  investigate  the  effects  of 
different parameters such as thiolated chitosan, 
methylmethacrylate, and different amounts of 
initiators on the size, zeta potential and shape, and 
in vitro mucoadhesive properties of nanoparticles 
(10). Also human complement activation was used 
to investigate in vivo fate of the nanoparticles after 
administration.  The  complement  system  is  a  key 
inflammatory mediator in immune complex diseases 
and complement sensitization of red blood cells 
(RBCs)  result  in  hemolysis.  Sheep  erythrocytes 
were sensitized with hemolysine and after addition 
of nanoparticles, the complement consumption was 
assessed in human serum (HS) by measurement of 
the hemolytic capacity of the complement system 
after contact with nanoparticles.
MATERIAL AND METHODS 
Materials
Chitosan  (low  molecular  weight,  degree  of 
deacetylation 98%) (Primex, Island), L-Cysteine HCl, 
L-Glutathione reduced form, Cerium ammonium 
nitrate (IV) and Monomer Methylmethacrylate (MMA) 
were purchased from Merck (Germany) 1-Ethyl-3-(3-
Dimethylaminopropyl Carbodiimide hydrochloride 
(EDAC),  Ellman’s  reagent  (5-5›-dithiobis(2-
nitrobenzoic  acid),  N-Hydroxysuccinimide  (NHS) 
and mucin type II (1% sialic acid) were purchased 
from Sigma-Aldrich (USA). All other chemicals were 
reagent grade and used as purchased.
Synthesis of chitosan conjugates
Glutathione  covalently  was  attached  to  chitosan 
according the methods described previously (5, 9).
Determination of the thiol group content
The  amount  of  thiol  groups  immobilized  on 
chitosan-GSH  conjugate  was  determined 
spectrophotometrically using Ellman’s reagent for 
quantification of free thiol groups (11). The amount of 
thiol moieties was calculated from the corresponding 
standard curve elaborated under the same conditions 
with  L-cysteine  HCl  solutions  (0-0.2  µmol/ml) 
(r2=0.9994).
Thiolated chitosan characterization
FT-IR  (Nicolet  550  FT-IR  Spectrophotometer, 
U.S.A) and HNMR (Bruker 500 Ultrashield-MHZ, 
Parameters
Formulation Amount of Initiator (ml) Amount of MMA (ml) Thiolated Chitosan (g)
A 2.00 0.50 0.138
B 2.00 0.50 0.000
C 2.00 0.50 0.069
D 2.00 0.50 0.276
E 2.00 0.25 0.138
F 2.00 1.00 0.138
G 1.00 0.50 0.138
Table 1.  Formulations of prepared nanoparticles with different amounts of thiolated chitosan, MMA and Initiator
Amount of thiolated 
chitosan (g)
Size of Nanoparticles 
(nm) ±SD
0.00 (Formulation B) 2155.30 ±42
0.07 (Formulation C) 388.70 ±8
0.14 (Formulation A) 334.00 ±12
0.28 (Formulation D) 924.30 ±18
Table 2. Effect of the amount of thiolated chitosan on the size 
of  nanoparticles  (n=3±SD).  (Amount  of  MMA=0.5  ml  and 
Initiator=2 ml) 
Table 3. Effect of the amount of MMA on the size of nanoparticles 
(n=3±SD). (0.138 g thiolated chitosan, 2 ml initiator)
Amount of MMA (ml) Size of Nanoparticles (nm) ±SD
0.25 (Formulation E) 382.23 ±12
0.5 (Formulation A) 334  ±12
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Germany) were used to show the formation of amide 
bonds between chitosan and glutathione. 
Preparation of thiolated chitosan coated 
nanoparticles of PMMA
Nanoparticles were prepared by radical emulsion 
polymerization, according to method described 
before (2). Briefly different amounts of solution 
of  thiolated  chitosan  (0.069g  and  0.276  g)  in 
nitric  acid  were  mixed  with  solution  of  cerium 
IV ammonium nitrate (1 ml, 2 ml) and MMA (1 
ml, 0.25 ml) at 40°C for 40 min. The medium was 
purified by dialysis against acetic acid solution in 
Milli-Q water twice for 90 min and once overnight. 
The prepared formulations are listed in table 1.
Nanoparticle characterization
The techniques of FT-IR and HNMR were used 
to display conjugation of thiolated chitosan to 
methylmethacrylate homopolymer. Nanoparticles 
were dissolved in D2O containing 0.1 M of DCl 
(Deuterochloric acid.)
Samples  were  diluted  in  Milli-Q  water.  The 
hydrodynamic mean diameter, the size distribution 
and  the  zeta  potential  of  all  formulations  were 
determined  at  20-25°C  using  Nano-Zeta  Sizer 
(Malvern Instruments, UK). The electric surface 
charge  of  the  polymer  particles  was  deduced 
from the electrophoretic mobility of the particles. 
Results corresponded to the average of three 
determinations.
All  formulated  suspensions  were  successively 
diluted  in  Milli-Q  water  to  1/100  (v/v).  The 
dilutions were spread on an aluminum disc and 
dried  at  room  temperature  in  a  desiccator.  The 
dried  nanoparticles  were  observed  under  gold-
plate under a scanning electron microscope 
(Philips XL30 Netherlands). Transmission electron 
microscopy was performed using a transmission 
electron  microscope  (TEM-CEM902A-ZWEISS 
Germany).
Bioadsorption and mucin assay study 
The  amount  of  mucin  adsorbed  by  2.0  mg  of 
Figure 1. FT-IR spectra of (a) chitosan, (b) thiolated chitosan, (c) PMMA, (d) polymethylmethacrylate nanoparticles coated with thiolated 
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nanoparticles in a certain period of time was used 
to determine mucoadhesion (12). At first, solution 
(0.5 mg/ml) of the type II of mucin was mixed with 
nanoparticle  solution  (4  mg/ml)  and  the  resulting 
solution was agitated with vortex and incubated at 
37°C for 16-18 hrs. Then the process was carried 
out for ten minutes using centrifugation at 10,000 
rpm.  Colorimetric  method  with  Periodic  Acid 
Schiff  (PAS)  Staining  (Schiff  Reagent  with  final 
concentration of 1.0%) was used in order to measure 
free mucin in the supernatant (13). Eighty milligram 
of sodium bisulphate was added to 5 ml of Schiff 
reagent and solution was incubated at 37° C until it 
became colorless or pale yellow. Ten microliter of 
50% periodic acid was added to 7 ml of 7% acetic 
acid to prepare freshly Periodic Acid Schiff Solution. 
Supernatants  were  added  to  the  diluted  periodic 
acid and incubated for 2 hrs at 37°C. Then 100 µl 
of Schiff reagent was added at room temperature 
and absorbance was measured at 560 nm after thirty 
minutes. Concentration of mucin in solution before 
and after adsorption by the chitosan nanoparticles 
was measuresd to determine mucoadhesion. Mucin 
standards (0.1, 0.25 and 0.5 mg/ml) were measured 
by the same procedure.
Complement consumption studies
Complement consumption was assessed according 
to the described method (14) in human serum (HS) 
by measurement of the hemolytic capacity of the 
complement system after contact with nanoparticles. 
Briefly 100 µl of HS was added to various amounts 
of  the  nanoparticle  suspensions  (50,  100,  125, 
150,  200  and  250  µl  and  the  suspensions  were 
incubated  at  37°C  for  60  min.  Simultaneously, 
sheep erythrocytes were sensitized with hemolysine 
diluted at 1:1, 600 (v/v) in VBS2+ and suspended 
to  a  final  concentration  of  1.108  cells/ml.  After 
incubation, different amounts of the mixture of 
nanoparticles/serum  (0.2,  0.25,  0.3,  0.35,  0.4  and 
0.6 ml) were diluted with VBS2+to reach a total 
volume of 0.8 ml. The sensitized sheep erythrocytes 
(0.2  ml)  were  also  added  and  the  samples  were 
incubated at 37°C for 45 min. Following addition of 
2 ml of NaCl, unlysed erythrocytes were separated 
by centrifugation and lyses of cells were measured 
at 405 nm.  Results were expressed as CH50 units 
consumption(11).  (The  CH50  unit  represents  the 
concentration of hemolytic complement units per 
ml of serum able to cause 50% hemolysis of a fixed 
volume of these sheep red cells.)
RESULTS
Characterization of chitosan-GSH conjugate 
Chitosan-GSH  conjugate  was  synthesized  by 
the  amide  bond  formation  between  carboxylic 
acid groups of glycine carboxylic acid groups of 
glutathione and amine groups of chitosan in the 
presence of EDAC (15, 16). 
The  by-products  during  cross-linking  of  EDAC/
NHS are water-soluble and can be easily removed 
by rinsing. The content of immobilized thiol groups 
strongly depends on the EDAC/NHS concentration 
and  the  molar  ratio  used.  The  optional  coupling 
conditions were defined: Polymer/GSH ratio of 1:5, 
pH 5.5-6.0, and a reaction time of 7 hrs.
The conjugate exhibited 239.8 µmol of immobilized 
free thiol group per gram of polymer. FT-IR and 
1HNMR spectra of chitosan and thiolated chitosan 
(Figs 1 and 2) confirmed the presence of thiol group 
at the surface of chitosan (Fig. 2).
Determination of the nanoparticle characteristics
IR spectrum of the thiolated chitosan-poly-
methylmethacrylate conjugate showed the carbonyl 
absorption peak at 1731.44/cm-1 (Fig. 1, Part C) for the 
homopolymer  poly-methylmethacrylate  (PMMA). 
In the conjugate co-polymer the presence of the 
carbonyl absorption peak at 1736.56 cm-1 confirmed 
the conjugation reaction between thiolated chitosan 
and PMMA (Fig. 1). The peaks of 1.66 ppm and 
1.68 ppm in 1HNMR spectrum of thiolated chitosan-
PMM conjugate is related to the methylene and 
methyl groups of methylmethacrylate. In addition 
the lack of the peak around 3.64 ppm (located at 3.4-
3.64 ppm) related to the O-methyl group of methyl 
methacrylate in thiolated chitosan, but present at 
the PMM spectrum also confirmed the formation of 
the copolymer (of  methylmethacrylate coated with 
thiolated chitosan) as shown in figure 2 (17).
Nanoparticle characteristics
As  shown  in  table  2,  the  particles  ranging  from 
334 to 940 nm were obtained for thiolated chitosan 
formulations. In the absence of thiolated chitosan 
(formulation  B)  larger  particles  (P  0.0001)  were 
formed.  On  the  other  hand  when  the  amount  of 
thiolated chitosan and MMA were 0.069 g and 0.5 
ml respectively (Formulation C), the size of particles 
increased, occurring at around 388.7 nm (P<0.05). 
The increase in thiolated chitosan to two-folds leads 
to an increase in nanoparticle size (formulation D: 
2 ml initiator, 0.50 ml MMA, at 0.276 g chitosan, 
924.30 nm) (P<0.0001).
Table 3 shows the effects of different amounts of 
MMA on particle size (at 0.138 g thiolated chitosan). 
When the amount of MMA was 0.25 (formulation 
E) and 0.5 ml (formulation A), the particle size were 
382.23  and  334  nm,  respectively  (P<0.05).  The 
increase of MMA to 1ml (formulation F) led to larger 
particles of 570 nm (P<0.001). As for the effect of 
different amounts of initiator, it may only assumed 
a lack of predictability with the initiator, showing it 
only catalyzes without being dose-dependent (data 
not shown).
The zeta potential for all formulations was positive, 
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covered the surface of the nanoparticles. There was 
a  significant  difference  between  formulations  A 
and B, due to a reduction in the zeta potential of 
formulation B (P < 0.001). The PMM with thiolated 
chitosan clearly increased Zeta potential (59.13 mV) 
while the PMM not covered with chitosan (without 
Figure 3. Scanning eletron microscopy image of 
polymethylmethacrylate  nanoparticles  coated  with  thiolated 
chitosan.
 Figure  4.  Transmission  electron  microscopy  image  of
 polymethylmethacrylate  nanoparticles  coated  with  thiolated
.chitosan
thiol  addition)  showed  marked  reduction  in  Zeta 
potential (18.026 mV).
In  figures  3  and  4  SEM  and  TEM  micrographs 
showed populations of spherical nanoparticles for 
all formulations except formulation B.
Nanoparticle mucoadhesion 
Mucin, a glycoprotein, is the major component of 
the mucus that coats the cells lining, the surfaces of 
the respiratory, digestive and urogenital tracts (18). 
Mucoadhesiveness of nanoparticles was calculated 
as the amount of mucin adsorbed by 2 mg of thiolated 
chitosan nanoparticles in a certain period of time 
(n=2). Absence of  thiolated chitosan (formulation 
B) led to lowest mucoadhehesion (29%). As shown 
in figure 5 when the amount of MMA was 0.5 ml 
and thiolated chitosan was 0.069 g (formulation C), 
0.138 g (formulation A) and 0.276 g (formulation D), 
mucoadhesivity were 83, 91 and 86%, respectively. 
Figure 2. 1HNMR spectra of (a) chitosan, (b) thiolated chitosan, 
(c)  PMMA,  (d)  polymethylmethacrylate  nanoparticles  coated 
with thiolated chitosan.
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solution was agitated with vortex and incubated at 
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out for ten minutes using centrifugation at 10,000 
rpm. Colorimetric method with Periodic Acid 
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concentration of 1.0%) was used in order to measure 
free mucin in the supernatant (13). Eighty milligram 
of sodium bisulphate was added to 5 ml of Schiff 
reagent and solution was incubated at 37° C until it 
became colorless or pale yellow. Ten microliter of 
50% periodic acid was added to 7 ml of 7% acetic 
acid to prepare freshly Periodic Acid Schiff Solution. 
Supernatants were added to the diluted periodic 
acid and incubated for 2 hrs at 37°C. Then 100 µl 
of Schiff reagent was added at room temperature 
and absorbance was measured at 560 nm after thirty 
minutes. Concentration of mucin in solution before 
and after adsorption by the chitosan nanoparticles 
was measuresd to determine mucoadhesion. Mucin 
standards (0.1, 0.25 and 0.5 mg/ml) were measured 
by the same procedure.
Complement consumption studies
Complement consumption was assessed according 
to the described method (14) in human serum (HS) 
by measurement of the hemolytic capacity of the 
complement system after contact with nanoparticles. 
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incubation, different amounts of the mixture of 
nanoparticles/serum (0.2, 0.25, 0.3, 0.35, 0.4 and 
0.6 ml) were diluted with VBS2+to reach a total 
volume of 0.8 ml. The sensitized sheep erythrocytes 
(0.2 ml) were also added and the samples were 
incubated at 37°C for 45 min. Following addition of 
2 ml of NaCl, unlysed erythrocytes were separated 
by centrifugation and lyses of cells were measured 
at 405 nm.  Results were expressed as CH50 units 
consumption(11). (The CH50 unit represents the 
concentration of hemolytic complement units per 
PORIVHUXPDEOHWRFDXVHKHPRO\VLVRID¿[HG
volume of these sheep red cells.)
RESULTS
Characterization of chitosan-GSH conjugate 
Chitosan-GSH conjugate was synthesized by 
the amide bond formation between carboxylic 
acid groups of glycine carboxylic acid groups of 
glutathione and amine groups of chitosan in the 
presence of EDAC (15, 16).
The by-products during cross-linking of EDAC/
NHS are water-soluble and can be easily removed 
by rinsing. The content of immobilized thiol groups 
strongly depends on the EDAC/NHS concentration 
and the molar ratio used. The optional coupling 
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at the surface of chitosan (Fig. 2).
Determination of the nanoparticle characteristics
IR spectrum of the thiolated chitosan-poly-
methylmethacrylate conjugate showed the carbonyl 
absorption peak at 1731.44/cm-1 (Fig. 1, Part C) for the 
homopolymer poly-methylmethacrylate (PMMA). 
In the conjugate co-polymer the presence of the 
carbonyl absorption peak at 1736.56 cm-1FRQ¿UPHG
the conjugation reaction between thiolated chitosan 
and PMMA (Fig. 1). The peaks of 1.66 ppm and 
1.68 ppm in 1HNMR spectrum of thiolated chitosan-
PMM conjugate is related to the methylene and 
methyl groups of methylmethacrylate. In addition 
the lack of the peak around 3.64 ppm (located at 3.4-
3.64 ppm) related to the O-methyl group of methyl 
methacrylate in thiolated chitosan, but present at 
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the copolymer (of  methylmethacrylate coated with 
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Nanoparticle characteristics
As shown in table 2, the particles ranging from 
334 to 940 nm were obtained for thiolated chitosan 
formulations. In the absence of thiolated chitosan 
(formulation B) larger particles (P 0.0001) were 
formed. On the other hand when the amount of 
thiolated chitosan and MMA were 0.069 g and 0.5 
ml respectively (Formulation C), the size of particles 
increased, occurring at around 388.7 nm (P<0.05). 
The increase in thiolated chitosan to two-folds leads 
to an increase in nanoparticle size (formulation D: 
2 ml initiator, 0.50 ml MMA, at 0.276 g chitosan, 
924.30 nm) (P<0.0001).
Table 3 shows the effects of different amounts of 
MMA on particle size (at 0.138 g thiolated chitosan). 
When the amount of MMA was 0.25 (formulation 
E) and 0.5 ml (formulation A), the particle size were 
382.23 and 334 nm, respectively (P<0.05). The 
increase of MMA to 1ml (formulation F) led to larger 
particles of 570 nm (P<0.001). As for the effect of 
different amounts of initiator, it may only assumed 
a lack of predictability with the initiator, showing it 
only catalyzes without being dose-dependent (data 
not shown).
The zeta potential for all formulations was positive, 
indicating that the cationic polysaccharide had indeed 
covered the surface of the nanoparticles. There was 
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and B, due to a reduction in the zeta potential of 
formulation B (P < 0.001). The PMM with thiolated 
chitosan clearly increased Zeta potential (59.13 mV) 
while the PMM not covered with chitosan (without 
thiol addition) showed marked reduction in Zeta 
potential (18.026 mV).
Fig 2. 1HNMR spectra of (a) chitosan, (b) thiolated chitosan, (c) 
PMMA, (d) polymethylmethacrylate nanoparticles coated with 
thiolated chitosan
Fig 3. Scanning eletron microscopy image of polymethylmethacrylate
nanoparticles coated with thiolated chitosan
Fig.4. Transmission electron microscopy image of
polymethylmethacrylate nanoparticles coated with thiolated
chitosan
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showed populations of spherical nanoparticles for 
all formulations except formulation B.
Nanoparticle mucoadhesion 
Mucin, a glycoprotein, is the major component of 
the mucus that coats the cells lining, the surfaces of 
the respiratory, digestive and urogenital tracts (18). 
Mucoadhesiveness of nanoparticles was calculated 
as the amount of mucin adsorbed by 2 mg of thiolated 
chitosan nanoparticles in a certain period of time 
(n=2). Absence of thiolated chitosan (formulation 
B) led to lowest mucoadhehesion (29%). As shown 
LQ¿JXUHZKHQWKHDPRXQWRI00$ZDVPO
and thiolated chitosan was 0.069 g (formulation C), 
0.138 g (formulation A) and 0.276 g (formulation D), 
mucoadhesivity were 83, 91 and 86%, respectively. 
The highest value of the mucoadhesivity (98%) was 
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The highest value of the mucoadhesivity (98%) was 
obtained  for  formulation  E.  According  to  figure 
5, there is not any direct correlation between the 
amount of thiolated chitosan and mucoadhesivity.
Complement consumption studies
Consumption of CH50 units in the presence of particles 
was assessed at a constant incubation time. The results 
are the mean of two determinations with a standard 
deviation of approximately 7%. Strong complement 
activation occurred in the presence of formulation C 
(98%). On the contrary, formulation B did not induce 
any system response (25%). The formulations D and A 
also did not induce any strong complement activation 
respectively  (45%,  50%),  indicating  that  only  the 
presence of chitosan tightly bound to thiol groups 
induces  a  full  complement  response. As  shown  in 
table 4 formulation G (0.5 ml MMA, 0.138 g thiolated 
chitosan) led to 60% complement activatioin, whereas 
formulation F (1 ml MMA, 0.138 g thiolated chitosan) 
led  to  95%  complement  activation.  On  the  other 
hand  there  was  not  any  direct  correlation  between 
the amount of thiolated chitosan and complement 
activation.
DISCUSSION 
Over the years, mucoadhesive polymers have shown 
to be able to adhere to various mucosal membranes. 
Moreover, using such polymers, the degradation 
of orally administered peptide drugs by intestinal 
enzymes can be avoided and permeation enhancing 
effects (or the inhibition of brush border membrane-
bound enzymes) become feasible (19). Within recent 
years, the deacetylated form of chitin – chitosan  has 
received considerable attention as a novel incipient 
in  drug  delivery  systems  (20,21).  Trimethylated 
chitosan,  mono-N-carboxymethyl  chitosans  (22), 
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Figure 5. Effects of different amounts of MMA and thiolated chitosan on mucoadhesion (A=0.138g thiolated chitosan, 0.50 ml MMA; 
B=0.000g thiolated chitosan, 0.50 ml MMA; C=0.069g thiolated chitosan, 0.50 ml MMA; D=0.276g thiolated chitosan, 0.50 ml MMA; 
E=0.138g thiolated chitosan, 0.25 ml MMA; F=0.138g thiolated chitosan, 1.00 ml MMA; G=0.138g thiolated chitosan, 0.50 ml MMA) 
(n=2±SD).
N-sulfo-chitosan (23) or chitosan-EDTA conjugates 
(24) were synthesized to improve the properties of 
the polymer (21). 
Thiolated polymers (thiomers) improve the uptake 
of hydrophilic macromolecules from the GI tract. 
Thiol groups inhibit protein tyrosine phosphatase, 
and is involved in the closing process of tight 
junctions,  via  a  GSH-mediated  mechanism  (25). 
Moreover, focusing on the structure of GSH as a 
non-toxic ligand, because of the presence of the thiol 
group in the tripeptide structure and its high negative 
redox potential, the Chitosan-GSH exhibited higher 
permeation-enhancing properties compared to other 
thiomers and so the Chitosan-GSH conjugate is 
more stable (9). The presence of thiol groups in the 
modified polymers promote the formation of inter-
and intra-chain disulfide bonds. 
For the preparation of nanoparticles in the present 
study a method called free radical emulsion 
polymerization was used. Nano-sized particles with 
a central core composed of polymethylmethacrylate 
and a surface covered by high-polar macromonomer 
chains of thiolated chitosan were obtained as shown 
in figure 7. Nanoparticles are formed simultaneously 
by polymerization of methylmethacrylate, and the 
process promotes at one stage spontaneously. Cerium 
(IV) ammonium nitrate is used as the initiator of this 
process.  
The molecular weight of polymeric chains has an 
impact  on  the  mucoadhesive  properties.  Tensile 
studies with chitosan-TBA conjugates have indicated 
that medium molecular mass thiolated chitosans 
display relatively highest mucoadhesiveness (26). 
The  particle  size  in  this  study  was  found  to  be 
around 334-650 nm. When the amount of reactants, 
including thiolated chitosan, methylmethacrylate 
monomer, and initiator amount, were 0.138 g, 0.5 ml, Talaei et al / DARU 2011 19 (4) 257-265 263
2 ml respectively (formulation A), the particle size 
was around 334 nm and the shape was spherical. The 
absence of thiolated chitosan led to the formation of 
particles with larger size (formulation B).  It may 
be also supposed that without chitosan nanoparticles 
become obsolete. Hence the presence of thiolated 
chitosan is required for the synthesis of nanoparticles, 
but acts as a dose dependent parameter  i.e. in lowest 
or the highest concentrations larger particles are 
obtained (as shown in formulations C, D).
The zeta potential for all formulations was positive 
and in the same range, except for “formulation B: 
which  had  no  thiolated  chitosan”.  The  particle 
sizes of all nanoparticles measured by a zetasizer 
nanosizer  were  larger  than  those  obtained  by 
quantitative  analysis  of  the  transmission  electron 
micrographs or scanning electron micrographs. This 
is because the contrast of the TEM pictures allows 
only the visualization of nanoparticle core, whereas 
hydrodynamic radiuses of the particles are measured 
by the zeta sizer (27).
Studies  show  that  chitosan  acts  as  a  promising 
bioadhesive material. It has been suggested that 
amino groups of chitosan interact with negatively 
charged group in biological membrane and increase 
mucoadhesivity (28). It has also been reported that 
the covalent attachment of thiol groups to polymers 
greatly increases mucoadhesiveness and permeation 
properties  without  affecting  biodegradability  (4, 
29). From the results of this study it is hypothesized 
that the absorption of the drugs through mucosa 
could be enhanced by administration of thiolated 
chitosan nanoparticles because of their greater 
mucoadhesiveness and permeability properties. 
Results show that thiolated chitosan nanoparticles 
bind mucin II (containing 1% sialic acid), and this 
is  shown  by  increased  mucoadhesiveness  in  the 
presence of chitosan Fig. 5. In this reaction, positive 
charges of thiolated chitosan can adhere to the 
negatively charged mucus layer by establishment 
of electrostatic interactions (30). According to the 
figure 5, amount of thiolated chitosan did not have 
significant  impact  on  mucoadhesivity  and  there 
was not any direct correlation with the amount of 
thiolated chitosan and mucoadhesivity.
Another useful technique for nanoparticle surface 
characterization  is  complement  activation.  This 
method  was  found  to  give  a  good  predictive 
result of the in vivo fate of the nanoparticles after 
administration, especially regarding their uptakes by 
the macrophages (MPS). It has been demonstrated 
that surface properties of nanoparticles are the key 
factors that determine their in vivo fates (31-33). 
 In this study the degree of complement activation 
was  studied  by  hemolytic  complement  assay. 
Complement activation led to the massive 
production of complement molecules that act 
as  enzymes  for  subsequent  chemical  reactions, 
resulting in cell lysis.  As it is shown in table 4 the 
presence of thiolated chitosan affected nanoparticle 
solution by the activation of complement in a dose 
dependent manner. Absence of thiolated chitosan 
led to particles (even those with a larger size) unable 
to activate the complements. On the other hand 
increasing the amount of thiolated chitosan led to 
complement activation. The remaining formulations 
induced complement activation as follows: F: 95%, 
E: 82.5%, G: 60%. Studies show that activation of 
complement has correlation with free NH2  groups of 
chitosan (34).  
CONCLUSIONS
Within  this  study,  a  new  effective  radical 
polymerization method was used to synthesize and 
conjugate thiolated chitosan to methyl methacrylate 
homopolymers (in this case PMMA) and tested to 
confirm their effectiveness in (hydrophilic polymer 
Formulation Amount of Initiator (ml) Amount of MMA (ml) Thiolated Chitosan (g) CH50 units consumed % (±SD)
A 2.000 0.500 0.138 50±7.07
B 2.000 0.500 0.000 25±7.07
C 2.000 0.500 0.069 98±0
D 2.000 0.500 0.276 45±7.07
E 2.000 0.250 0.138 82.5±3.53
F 2.000 1.000 0.138 95±1.41
G 1.000 0.500 0.138 60±7.07
Table 4. Effect of different formulations on human complement activation. (n=2±SD).
Figure 6. Schematic representation of designed nanoparticle form
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